908Angiogenesis: AACR Childhood Leukemia
- Sep 29, 1998Greetings,
I thought I would share some more information we picked up at THE MARCH.
Leukemia is a cousin to lymphoma. Lymphoma is more than twice as common as
First a background:
"Leukemia is a malignant disease (cancer) of the bone marrow and blood. It is
characterized by the uncontrolled growth of blood cells. The common types of
leukemia are divided into four categories: myelogenous or lymphocytic, which
can be acute or chronic. The terms myelogenous or lymphocytic denote the cell
type involved. Thus, the four major types of leukemia are: acute or chronic
myelogenous and acute or chronic lymphocytic leukemia."
Total Projected 1998 Leukemia Diagnosis: 28,700
Total Projected 1998 Leukemia Deaths: 21,600
Facts: Leukemia is expected to strike ten times as many adults as children in
1998. (About 26,500 cases compared with 2,200 in children, ages 0-14.) More
than half of all cases of leukemia occur in persons over 60.
"Lymphoma is a general term for a group of cancers that originate in the
lymphatic system, which includes hundreds of bean-size lymph nodes, present
throughout the body, and the spleen and thymus.
Lymphoma results when a lymphocyte (a type of white blood cell) undergoes a
malignant change and begins to multiply, eventually crowding out healthy cells
and creating tumors which enlarge lymph nodes."
(Note: Could one of the 'changes' be angiogenesis? we will watch-wait-worry
tuned the whole time to the Hope Channel)
Total Projected 1998 Lymphoma Diagnoses: 62,500
Total Projected 1998 Lymphoma Deaths: 26,300
The following was found in a folder from the American Association for Cancer
Research (AACR) entitled: "Progress and New Hope in the Fight Against Cancer"
AACR Public Forum Highlighting the Latest Discoveries:
Saturday, September 26, 1998 - Washington, D.C.
In one of the handouts entitled, "Childhood Cancers" on page 1-2.
"The recent discovery that human leukemia has an angiogeneic phase (when
leukemic cells must form their own network of blood vessels to ensure vigorous
growth) has led to efforts to combat this disease through disruption of its
vascular support system. In preliminary studies, endostatin, a naturally
occurring protein with antiangiogenic activity, eradicated leukemia in all
that received the compound, without harming normal cells. Although it is not
clear how leukemia patients will respond to antiangiogenic agents, this is a
novel approach that may someday become part of first-line combination
Note: Blanket reference of Leukemia (That looks like all 4 types to me.)
(We wait for TNP-470 to begin Phase I trials the end of the year with
Leukemia and Lymphoma)